Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 23, 2014 - Issue 8
Submit an article Journal homepage
453
Views
27
CrossRef citations to date
0
Altmetric
Drug Evaluations

Mavoglurant as a treatment for Parkinson’s disease

Dmitry PetrovUniversitat de Barcelona, Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Unitat de Farmacologia I Farmacognòsia, Facultat de Farmàcia, Barcelona, Avda/Joan XXIII, [email protected]
,
Ignacio PedrosUniversitat Rovira i Virgili, Unitat de Bioquimica i Biotecnología, Facultat de Medicina i Ciències de la Salut, Reus, Tarragona, Spain
,
Maria Luisa de LemosUniversitat de Barcelona, Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Unitat de Farmacologia I Farmacognòsia, Facultat de Farmàcia, Barcelona, Avda/Joan XXIII, [email protected]
,
Mercè PallàsUniversitat de Barcelona, Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Unitat de Farmacologia I Farmacognòsia, Facultat de Farmàcia, Barcelona, Avda/Joan XXIII, [email protected]
,
Anna Maria CanudasUniversitat de Barcelona, Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Unitat de Farmacologia I Farmacognòsia, Facultat de Farmàcia, Barcelona, Avda/Joan XXIII, [email protected]
,
Alberto LazarowskiUniversidad de Buenos Aires (UBA), Instituto de Investigaciones en Fisiopatología y Bioquímica Clínica (INFIBIOC), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina
,
Carlos Beas-ZarateUniversidad de Guadalajara and División de Neurociencias, Departamento de Biología Celular y Molecular, C.U.C.B.A, Sierra Mojada 800, Col. Independencia, Guadalajara, Jalisco 44340, México;Instituto Mexicano del Seguro Social (IMSS), Centro de Investigación Biomédica de Occidente (CIBO), Jalisco 44340, México
,
Carme AuladellUniversitat de Barcelona, Departament de Biologia Cellular, Facultat de Biologia, Barcelona, Spain
,
Jaume FolchUniversitat Rovira i Virgili, Unitat de Bioquimica i Biotecnología, Facultat de Medicina i Ciències de la Salut, Reus, Tarragona, Spain
&
Antoni CaminsUniversitat de Barcelona, Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Unitat de Farmacologia I Farmacognòsia, Facultat de Farmàcia, Barcelona, Avda/Joan XXIII, [email protected]
 show all
Pages 1165-1179 | Published online: 24 Jun 2014

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Thomas Müller. (2017) Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 13:6, pages 693-699.
Read now
Kyle A. Emmitte. (2017) mGlu5 negative allosteric modulators: a patent review (2013 - 2016). Expert Opinion on Therapeutic Patents 27:6, pages 691-706.
Read now
Zsófia Majláth, Nóra Török, József Toldi & László Vécsei. (2016) Promising therapeutic agents for the treatment of Parkinson’s disease. Expert Opinion on Biological Therapy 16:6, pages 787-799.
Read now
Kjell Fuxe & Dasiel O Borroto-Escuela. (2015) Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opinion on Investigational Drugs 24:9, pages 1247-1260.
Read now
Ali Jazayeri & Fiona Marshall. (2015) Implications of metabotropic glutamate receptor structures for drug discovery in neurotherapeutics. Expert Review of Neurotherapeutics 15:2, pages 123-125.
Read now

Articles from other publishers (22)

Jace Jones-Tabah. (2023) Targeting G Protein-Coupled Receptors in the Treatment of Parkinson’s Disease. Journal of Molecular Biology 435:12, pages 167927.
Crossref
Daniel Garbin Di Luca, Nikolai Gil D. Reyes & Susan H. Fox. (2022) Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease. Drugs 82:10, pages 1027-1053.
Crossref
Wudtipong Vongthip, Chanin Sillapachaiyaporn, Kyu-Won Kim, Monruedee Sukprasansap & Tewin Tencomnao. (2021) Thunbergia laurifolia Leaf Extract Inhibits Glutamate-Induced Neurotoxicity and Cell Death through Mitophagy Signaling. Antioxidants 10:11, pages 1678.
Crossref
Ahmed Negida, Hazem S. Ghaith, Salma Yousry Fala, Hussien Ahmed, Eshak I Bahbah, Mahmoud Ahmed Ebada & Mohamed Abd Elalem Aziz. (2021) Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis. Neurological Sciences 42:8, pages 3135-3143.
Crossref
Cheng-lu Zhang, Qi-wen Han, Nai-hong Chen & Yu-he Yuan. (2021) Research on developing drugs for Parkinson's disease. Brain Research Bulletin 168, pages 100-109.
Crossref
Andrew Schneider, Adam T. Sari, Hasan Alhaddad & Youssef Sari. (2020) Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson’s Disease. CNS & Neurological Disorders - Drug Targets 19:3, pages 195-206.
Crossref
Mercè Pallàs, Santiago Vázquez, Coral Sanfeliu, Carles Galdeano & Christian Griñán-Ferré. (2020) Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson’s Disease: A New Therapeutic Strategy. Biomolecules 10:5, pages 703.
Crossref
Youwen Xu & Zizhong Li. (2019) Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development. Medicinal Research Reviews 39:5, pages 1892-1922.
Crossref
Branden J. Stansley & P. Jeffrey Conn. (2019) Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors. Trends in Pharmacological Sciences 40:4, pages 240-252.
Crossref
Pamela R. Westmark, Andrzej Dekundy, Andreas Gravius, Wojciech Danysz & Cara J. Westmark. (2018) Rescue of Fmr1 phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056. Neurobiology of Disease 119, pages 190-198.
Crossref
Tingting Fu, Guoxun Zheng, Gao Tu, Fengyuan Yang, Yuzong Chen, Xiaojun Yao, Xiaofeng Li, Weiwei Xue & Feng Zhu. (2018) Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations. ACS Chemical Neuroscience 9:6, pages 1492-1502.
Crossref
Samuel A. Barnes, Douglas J. Sheffler, Svetlana Semenova, Nicholas D.P. Cosford & Anton Bespalov. (2018) Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy. Biological Psychiatry 83:11, pages 955-962.
Crossref
Juan-Juan Du & Sheng-Di Chen. (2017) Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease. Chinese Medical Journal 130:15, pages 1856-1866.
Crossref
János Galambos, Attila Bielik, Gábor Wágner, György Domány, János Kóti, Zoltán Béni, Áron Szigetvári, Zsuzsanna Sánta, Zoltán Orgován, Amrita Bobok, Béla Kiss, Mónika L. Mikó-Bakk, Mónika Vastag, Katalin Sághy, Mikhail Krasavin, Krisztina Gál, István Greiner, Zsolt Szombathelyi & György M. Keserű. (2017) Discovery of 4-amino-3-arylsulfoquinolines, a novel non-acetylenic chemotype of metabotropic glutamate 5 (mGlu 5 ) receptor negative allosteric modulators. European Journal of Medicinal Chemistry 133, pages 240-254.
Crossref
Xavier Gómez-Santacana, James A.R. Dalton, Xavier Rovira, Jean Philippe Pin, Cyril Goudet, Pau Gorostiza, Jesús Giraldo & Amadeu Llebaria. (2017) Positional isomers of bispyridine benzene derivatives induce efficacy changes on mGlu5 negative allosteric modulation. European Journal of Medicinal Chemistry 127, pages 567-576.
Crossref
Wolfgang H. Oertel. (2017) Recent advances in treating Parkinson’s disease. F1000Research 6, pages 260.
Crossref
Adrian Hall. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III xv xxiv .
Maria Eliza Freitas & Susan H Fox. (2016) Nondopaminergic treatments for Parkinson's disease: current and future prospects. Neurodegenerative Disease Management 6:3, pages 249-268.
Crossref
Rajapillai L. I. Pillai & Dnyanesh N. Tipre. (2016) Metabotropic glutamate receptor 5 ? a promising target in drug development and neuroimaging. European Journal of Nuclear Medicine and Molecular Imaging 43:6, pages 1151-1170.
Crossref
Hoang Nam Vu, Ji Young Kim, Ahmed H.E. Hassan, Kihang Choi, Jong-Hyun Park, Ki Duk Park, Jae Kyun Lee, Ae Nim Pae, Hyunah Choo, Sun-Joon Min & Yong Seo Cho. (2016) Synthesis and biological evaluation of picolinamides and thiazole-2-carboxamides as mGluR5 (metabotropic glutamate receptor 5) antagonists. Bioorganic & Medicinal Chemistry Letters 26:1, pages 140-144.
Crossref
Marie-Therese Fuzzati-Armentero, Silvia Cerri, Giovanna Levandis, Giulia Ambrosi, Elena Montepeloso, Gianfilippo Antoninetti, Fabio Blandini, Younis Baqi, Christa E. Müller, Rosaria Volpini, Giulia Costa, Nicola Simola & Annalisa Pinna. (2015) Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease . Journal of Neurochemistry 134:4, pages 740-747.
Crossref
Lothar Lindemann, Richard H. Porter, Sebastian H. Scharf, Basil Kuennecke, Andreas Bruns, Markus von Kienlin, Anthony C. Harrison, Axel Paehler, Christoph Funk, Andreas Gloge, Manfred Schneider, Neil J. Parrott, Liudmila Polonchuk, Urs Niederhauser, Stephen R. Morairty, Thomas S. Kilduff, Eric Vieira, Sabine Kolczewski, Juergen Wichmann, Thomas Hartung, Michael Honer, Edilio Borroni, Jean-Luc Moreau, Eric Prinssen, Will Spooren, Joseph G. Wettstein & Georg Jaeschke. (2015) Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression. Journal of Pharmacology and Experimental Therapeutics 353:1, pages 213-233.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.